On this page
RBL2
RB transcriptional corepressor like 2
RBL2 is located on the long (q) arm of chromosome 16, at band 16q12.2. Arm ratio per GRCh38 - banding schematic.
Explore chromosome 16 in the library →Available at Jeen Health
Clinical tests that include this
Overview
RBL2 (RB transcriptional corepressor like 2) resides on chromosome 16 and belongs to the retinoblastoma family of cell cycle regulatory proteins. The protein encoded by this gene functions as a transcriptional corepressor, meaning it helps silence specific genes at critical points in the cell cycle. By controlling when certain genes are active, RBL2 contributes to the orderly progression of cell division and helps prevent premature entry into DNA replication phases. Understanding how RBL2 operates provides insight into fundamental mechanisms that maintain cellular organisation and prevent uncontrolled growth.
What the gene does
The RBL2 protein acts primarily as a transcriptional corepressor that regulates genes controlling cell cycle transitions. It binds to specific transcription factors, particularly those in the E2F family, and recruits additional regulatory proteins to block gene expression when cells should remain in a resting state or avoid premature division. This repressive function ensures that cells do not enter S phase (the DNA synthesis stage) until appropriate growth signals and checkpoint controls have been satisfied. Unlike some related proteins, RBL2 may have distinct roles in specific cell types or developmental contexts. The protein's activity is modulated by phosphorylation, which can alter its ability to bind transcription factors and chromatin. Through these mechanisms, RBL2 coordinates cellular responses to growth signals and helps maintain genomic integrity across successive rounds of cell division.
Video: Genetics 101
Chromosome location
RBL2 is located at chromosomal position 16q12.2 on the long arm of chromosome 16. The specific genomic architecture, including the number of exons and regulatory elements, contributes to how the gene is expressed across different tissues and developmental stages.
Protein structure
Domain architecture has not been experimentally characterised in detail for this protein.
Key variants
Genetic variants in RBL2 are documented in clinical databases, though the full spectrum of pathogenic changes remains under investigation. Variants may affect protein stability, binding interactions with transcription factors, or post-translational modification sites. The inheritance pattern for conditions linked to RBL2 variants can vary depending on the specific variant and associated phenotype.
No pathogenic or likely-pathogenic ClinVar variants recorded yet for this gene.
Associated conditions
At present, no specific inherited conditions have been formally linked to RBL2 variants in widely used clinical databases. Research continues to explore whether alterations in this gene contribute to developmental disorders, cancer predisposition, or other clinical phenotypes. The protein's role in cell cycle control suggests that disruption could theoretically influence processes related to growth regulation.
No disease links recorded for this gene in our reference set.
UK clinical status
Sources: NHS GMS PanelApp · Genomics England PanelApp · NHS National Genomic Test Directory
Frequently asked questions
What does RBL2 stand for?
RBL2 stands for RB transcriptional corepressor like 2. The name reflects its similarity to the retinoblastoma (RB) protein and its role in repressing gene transcription during cell cycle regulation.
How does RBL2 control the cell cycle?
RBL2 binds to transcription factors such as E2F proteins and prevents them from activating genes required for DNA synthesis. This keeps cells from dividing prematurely until appropriate signals are received.
Are RBL2 variants associated with cancer?
While RBL2 participates in pathways that regulate cell growth, specific inherited cancer syndromes linked to germline RBL2 variants have not been established in clinical databases. Research into its potential role in tumour development continues.